Middle East & Africa Vaccines Market Overview, Growth, Trends, Analysis, Research Report (2025-2031)
Middle East & Africa Vaccines Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Conjugated Vaccines, Inactivated Vaccines, Live Vaccines, Recombinant Vaccines, and Toxoid Vaccines), Indication (HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Other), Route of Administration (Injection, Oral, and Other), and Age Group (Pediatric and Adult)
- Status : Published
- Report Code : TIPRE00041548
- Category : Life Sciences
- No. of Pages : 198
- Available Report Formats :
The Middle East & Africa Vaccines Market size is expected to reach US$ 2,738.6 Million by 2031 from US$ 2,207.0 Million in 2024. The market is estimated to record a CAGR of 3.1% from 2025 to 2031.
Executive Summary and Middle East & Africa Vaccines Market Analysis:The MEA region's vaccines market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of MEA. Of these, the United Arab Emirates has the highest share and is a major hub for vaccine manufacture and distribution. This growth is driven by heavy investment in research and development, supported by developed infrastructure and sophisticated research facilities, majorly in the UAE and Saudi Arabia. The two nations have emphasized healthcare innovation, which created a profitable climate for scientific development in immunization. South Africa, however, will be forecast to face modest growth in the vaccine market in the coming years. This is primarily due to a boost in regional vaccine manufacturing by local pharmaceutical and biotech companies. With a focus on local manufacturing, South Africa seeks to curb import reliance, promoting cheaper vaccines and expanded access. All these efforts at the continental level cumulatively drive the dynamic of the MEA vaccine market.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Middle East & Africa Vaccines Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- By Type, the Middle East & Africa Vaccines Market is segmented into Conjugated Vaccines, Inactivated Vaccines, Live Vaccines, Recombinant Vaccines, and Toxoid Vaccines. The Conjugated Vaccines segment held the largest share of the market in 2024.
- By Indication, the Middle East & Africa Vaccines Market is segmented into HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Other. The HPV segment held the largest share of the market in 2024.
- By Route of Administration, the Middle East & Africa Vaccines Market is segmented into Injection, Oral, and Other. The injection segment held the largest share of the market in 2024.
- By Age Group, the Middle East & Africa Vaccines Market is segmented into Pediatric and Adult. The pediatric segment held a larger share of the market in 2024.
The vaccine industry is currently experiencing a transformative phase, with combination and therapeutic vaccines emerging as the most promising opportunities for manufacturers. Innovations in these vaccines not only address evolving public health challenges but also provide significant commercial and operational advantages.
Combination vaccines are formulations designed to protect against multiple diseases in a single shot. Traditionally used in pediatric care, as seen with vaccines like MMR (measles, mumps, rubella) and DTP (diphtheria, tetanus, pertussis), combination vaccines are now expanding their reach to adult and elderly populations. This is particularly relevant for respiratory illnesses such as influenza, COVID-19, and Respiratory Syncytial Virus (RSV). Combination vaccines can greatly improve immunization rates, resulting in a quicker and more extensive reduction in disease burden. They are especially important as new vaccines for diseases such as dengue, typhoid, RSV, and tuberculosis are being developed. According to Gavi, by 2030, combination vaccines will provide protection against 30 infections with fewer doses. Major pharmaceutical companies, including Moderna, Pfizer/BioNTech, Novavax, Sanofi, GSK, and AstraZeneca, are developing combination vaccines for COVID-19, influenza, and RSV. These products are anticipated to transform seasonal immunization strategies and enhance uptake among adults and elderly populations. Additionally, therapeutic vaccines are designed not to prevent diseases but to treat existing conditions, which can include chronic infections, cancers, and allergies. This approach represents a new frontier in vaccine technology, utilizing advancements in mRNA, viral vectors, and personalized medicine. For instance, cancer vaccines aim to stimulate the immune system to recognize and attack tumor cells. Additionally, some vaccines are being developed for chronic infections such as hepatitis B and HIV.
As of 2024, the US Food and Drug Administration (FDA) has approved three therapeutic vaccines: Sipuleucel-T for advanced prostate cancer, Bacillus Calmette-Guérin for high-risk, non-muscle-invasive bladder cancer, and Talimogene laherparepvec for melanoma. As research progresses, therapeutic vaccines are expected to become a significant segment within the broader vaccine market, addressing unmet medical needs and expanding the potential customer base. Several companies are currently under trial for therapeutic cancer vaccines aimed at cancers and other chronic diseases. These vaccines are designed to enhance the body's immune response against cancer cells and are often used alongside other treatment modalities.
Both combination and therapeutic vaccines align with global health priorities by improving access, reducing the disease burden, and addressing complex health challenges. Their development benefits from significant public and private investment, collaborative partnerships, and ongoing advancements in biotechnology.
Therefore, the development of combination and therapeutic vaccines presents substantial opportunities for vaccine manufacturers to grow, innovate, and create a meaningful impact. These vaccines simplify immunization, expand their applications, and address both preventive and therapeutic health needs worldwide.
By country, the Middle East & Africa Vaccines Market is segmented into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East & Africa. South Africa held the largest share in 2024.
South Africa is actively investing in local vaccine manufacturing, supported by government policies prioritizing preferential procurement, long-term contracts, and tax incentives for domestic producers. According to Gavi, the African Union (AU) aims to develop, produce, and supply over 60% of the continent's vaccine doses by 2040, a significant increase from the level of less than 1% in 2021. This ambitious goal will require coordinated efforts and a strategic action plan. As an initial step, the Partnerships for African Vaccine Manufacturing (PAVM) has been established under the Africa CDC. The South African government, in partnership with Gavi, UNICEF, and other organizations, has enhanced its immunization campaigns, particularly for COVID-19 and seasonal influenza. This focus is crucial, given the country's significant burden of comorbidities such as HIV and tuberculosis.
The introduction of new vaccine types, including subunit, mRNA, and viral vector vaccines, by both international and local manufacturers has expanded the vaccine options available in South Africa. Major global companies like Pfizer, BioNTech, Sanofi, and the Serum Institute of India are actively involved in the market, introducing advanced vaccines for diseases such as COVID-19, influenza, and HPV. In December 2023, the International Finance Corporation (IFC) announced a 7 million rand loan and advisory support for Biovac to improve vaccine production and pandemic preparedness in Africa. The funding supported Biovac's production of various vaccines, including HPV and cholera. Additionally, IFC will collaborate with Biovac on a new multi-vaccine production plant in Cape Town, increasing production capacity from 150 million to about 560 million doses annually. This initiative aims to enhance local capabilities for producing both traditional bacterial-based and mRNA vaccines, reducing Africa's dependency on vaccine imports.
Middle East & Africa Vaccines Market Company ProfilesSome of the key players operating in the market include Abbott Laboratories, GSK Plc, Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, CSL Ltd, Serum Institute of India Pvt Ltd, BioNTech SE, and Sinovac Biotech Ltd.
These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
Middle East & Africa Vaccines Market Research MethodologyThe following methodology has been followed for the collection and analysis of data presented in this report:
Secondary Research
The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Company websites,
annual reports, financial statements, broker analyses, and investor presentationsIndustry trade journals
and other relevant publicationsGovernment documents,
statistical databases, and market reportsNews articles,
press releases, and webcasts specific to companies operating in the market
Note:
All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.Primary Research
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
- Validate and refine findings from secondary research
- Enhance the expertise and market understanding of the analysis team
- Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
Industry stakeholders:
Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales ManagersExternal experts:
Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. Vaccines Market Landscape
4.1 Market Overview
4.2 PEST Analysis
5. Middle East & Africa Vaccines Market - Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. Vaccines Market - Middle East & Africa Market Analysis
6.1 Middle East & Africa Vaccines Market Revenue (US$ Million), 2024 - 2031
6.2 Middle East & Africa Vaccines Market Forecast and Analysis
7. Middle East & Africa Vaccines Market Revenue Analysis - by Type
7.1 Conjugated
7.1.1 Overview
7.1.2 Conjugated: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Inactivated
7.2.1 Overview
7.2.2 Inactivated: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Live
7.3.1 Overview
7.3.2 Live: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.4 Recombinant
7.4.1 Overview
7.4.2 Recombinant: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.5 Toxoid
7.5.1 Overview
7.5.2 Toxoid: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. Middle East & Africa Vaccines Market Revenue Analysis - by Indication
8.1 HPV
8.1.1 Overview
8.1.2 HPV: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 PCV
8.2.1 Overview
8.2.2 PCV: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 DTP
8.3.1 Overview
8.3.2 DTP: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.4 Hepatitis
8.4.1 Overview
8.4.2 Hepatitis: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.5 Influenza
8.5.1 Overview
8.5.2 Influenza: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.6 Dengue
8.6.1 Overview
8.6.2 Dengue: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.7 Other
8.7.1 Overview
8.7.2 Other: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. Middle East & Africa Vaccines Market Revenue Analysis - by Route Of Administration
9.1 Injection
9.1.1 Overview
9.1.2 Injection: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Oral
9.2.1 Overview
9.2.2 Oral: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Other
9.3.1 Overview
9.3.2 Other: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. Middle East & Africa Vaccines Market Revenue Analysis - by Age Group
10.1 Pediatric
10.1.1 Overview
10.1.2 Pediatric: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. Middle East & Africa Vaccines Market - Country Analysis
11.1 Middle East & Africa
11.1.1 Middle East & Africa Vaccines Market Revenue and Forecast and Analysis - by Country
11.1.1.1 Middle East & Africa Vaccines Market Revenue and Forecast and Analysis - by Country
11.1.2.2 Saudi Arabia: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 Saudi Arabia: Middle East & Africa Vaccines Market Share - by Type
11.1.2.2.2 Saudi Arabia: Middle East & Africa Vaccines Market Share - by Indication
11.1.2.2.3 Saudi Arabia: Middle East & Africa Vaccines Market Share - by Route Of Administration
11.1.2.2.4 Saudi Arabia: Middle East & Africa Vaccines Market Share - by Age Group
11.2.3.3 South Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 South Africa: Middle East & Africa Vaccines Market Share - by Type
11.2.3.3.2 South Africa: Middle East & Africa Vaccines Market Share - by Indication
11.2.3.3.3 South Africa: Middle East & Africa Vaccines Market Share - by Route Of Administration
11.2.3.3.4 South Africa: Middle East & Africa Vaccines Market Share - by Age Group
11.3.4.4 United Arab Emirates: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 United Arab Emirates: Middle East & Africa Vaccines Market Share - by Type
11.3.4.4.2 United Arab Emirates: Middle East & Africa Vaccines Market Share - by Indication
11.3.4.4.3 United Arab Emirates: Middle East & Africa Vaccines Market Share - by Route Of Administration
11.3.4.4.4 United Arab Emirates: Middle East & Africa Vaccines Market Share - by Age Group
11.4.5.5 Rest of Middle East & Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4.5.5.1 Rest of Middle East & Africa: Middle East & Africa Vaccines Market Share - by Type
11.4.5.5.2 Rest of Middle East & Africa: Middle East & Africa Vaccines Market Share - by Indication
11.4.5.5.3 Rest of Middle East & Africa: Middle East & Africa Vaccines Market Share - by Route Of Administration
11.4.5.5.4 Rest of Middle East & Africa: Middle East & Africa Vaccines Market Share - by Age Group
12 Competitive Landscape
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 Industry Landscape
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 GSK Plc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Pfizer Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Merck & Co Inc
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Novartis AG
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Sanofi SA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 CSL Ltd
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Serum Institute of India Pvt Ltd
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 BioNTech SE
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Sinovac Biotech Ltd
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
List of Tables
Table 1. Middle East & Africa Vaccines Market Segmentation
Table 2. List of Vendors
Table 3. Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
Table 6. Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 7. Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Age Group
Table 8. Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. Saudi Arabia: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 10. Saudi Arabia: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
Table 11. Saudi Arabia: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 12. Saudi Arabia: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Age Group
Table 13. South Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 14. South Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
Table 15. South Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 16. South Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Age Group
Table 17. United Arab Emirates: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 18. United Arab Emirates: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
Table 19. United Arab Emirates: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 20. United Arab Emirates: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Age Group
Table 21. Rest of Middle East & Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 22. Rest of Middle East & Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
Table 23. Rest of Middle East & Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 24. Rest of Middle East & Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Age Group
Table 25. Heat Map Analysis by Key Players
List of Figures
Figure 1. Middle East & Africa Vaccines Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Vaccines Market
Figure 4. Middle East & Africa Vaccines Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Middle East & Africa Vaccines Market Revenue (US$ Million), 2024 - 2031
Figure 7. Middle East & Africa Vaccines Market Share (%) - by Type, 2024 and 2031
Figure 8. Conjugated: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Inactivated: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Live: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 11. Recombinant: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Toxoid: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Middle East & Africa Vaccines Market Share (%) - by Indication, 2024 and 2031
Figure 14. HPV: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. PCV: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. DTP: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Hepatitis: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Influenza: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Dengue: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Other: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Middle East & Africa Vaccines Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 22. Injection: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Oral: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Other: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Middle East & Africa Vaccines Market Share (%) - by Age Group, 2024 and 2031
Figure 26. Pediatric: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Adult: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Middle East & Africa Vaccines Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 29. Saudi Arabia: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. South Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. United Arab Emirates: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 32. Rest of Middle East & Africa: Middle East & Africa Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Company Positioning & Concentration
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For